Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans.
The physiological importance and therapeutical interest of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) are still controversial. Panhypopituitarism is characterized by the absence of secretion of adrenal and gonadal steroids and thus the production of their metabolites. The conversion of DHEA given orally into delta 5 derivatives, androgens, androgen metabolites, and estrogens was studied in ten patients with complete panhypopituitarism. Sex steroid therapy was withdrawn for at least 2 months. Each patient received, at 1-month intervals and in a random order, two single oral doses of DHEA (50 mg and 200 mg) and placebo. During each treatment, urine samples were collected for 24 h, and blood samples were drawn at hourly intervals for 8 h. In patients with pituitary deficiency, plasma DHEA and DHEAS were not detectable and increased, with the 50 mg dose, up to levels observed in young adults. The administration of 200 mg of DHEA induced an increase of both steroids to supraphysiological plasma levels. A small increase of delta 5-androstenediol was observed. In contrast, the increase of plasma delta 4-androstenedione was important and dose dependent. DHEA was also converted into the potent sex steroid testosterone (T). The administration of a 50 mg dose of DHEA restored plasma T to levels similar to those observed in young women. The 200 mg dose induced an important increase of plasma T, slightly below the levels observed in normal men. The increase of plasma dihydrotestosterone levels was small at both doses of DHEA, in contrast with the large conversion of DHEA into androsterone glucuronide and androstanediol glucuronide. Finally, DHEA administration induced a significant and dose dependent increase of plasma estrogens and particularly of estradiol. In conclusion, this short term study demonstrates that: 1) panhypopituitarism is a model of interest to study the metabolism of DHEA; 2) in the absence of pituitary hormones and of adrenal and gonadal steroids, DHEA given orally is mainly converted into delta 4 derivatives, which in turn are strongly metabolized into 5 alpha-3keto-reduced steroids; 3) a significant increase of sex active hormones was observed in plasma after 200 and even 50 mg of DHEA. Thus, biotransformation of DHEA into potent androgens and estrogens may explain several of the reported beneficial actions of this steroid in aging people.
Young
J
J
Service d'Endocrinologie et des Maladies de la Reproduction, Hopital Bicêtre, France.
Couzinet
B
B
Nahoul
K
K
Brailly
S
S
Chanson
P
P
Baulieu
E E
EE
Schaison
G
G
D000328:Adult; D000368:Aged; D015113:Androstane-3,17-diol / Q000097:blood; D015114:Androstenediol / Q000097:blood; D000735:Androstenedione / Q000097:blood; D000738:Androsterone / Q000031:analogs & derivatives / Q000097:blood; D003687:Dehydroepiandrosterone / Q000097:blood / Q000378:metabolism*; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D013196:Dihydrotestosterone / Q000097:blood; D005260:Female; D006801:Humans; D007018:Hypopituitarism / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D010919:Placebos; D013739:Testosterone / Q000097:blood
D010919:Placebos; D013196:Dihydrotestosterone; C027927:androsterone glucuronide; D015113:Androstane-3,17-diol; D013739:Testosterone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D019314:Dehydroepiandrosterone Sulfate; D015114:Androstenediol; D000738:Androsterone